Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011485 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Rasheduzzaman Rashu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Mucosal-Associated Invariant T Cells, COVID-19, Vaccines. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. Additionally, MAIT cells sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unclear. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster virus-specific CD8 + T cell responses, and potentiate heterosubtypic anti-influenza protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency and Toll-like receptor 3 and type I interferon receptor signaling. The observed phenomenon was reproducible in female and male mice, and in both young and old animals. It could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Western University, London, Ontario, Canada.
- McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
- Krembil Centre for Stem Cell Biology, Molecular Medicine Research Laboratories, Robarts Research Institute, London, Ontario, Canada.
- Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: S M Mansour Haeryfar
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Rashu, R., Ninkov, M., Wardell, C. M., Benoit, J. M., Wang, N. I., Meilleur, C. E., D'Agostino, M. R., Zhang, A., Feng, E., Saeedian, N., Bell, G. I., Vahedi, F., Hess, D. A., Barr, S. D., Troyer, R. M., Kang, C. Y., Ashkar, A. A., Miller, M. S., & Haeryfar, S. M. M. (2023). Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011485
Vancouver
Rashu R, Ninkov M, Wardell CM, Benoit JM, Wang NI, Meilleur CE, et al. Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011485
BibTeX
@article{Rashu2023,
author = {Rashu, Rasheduzzaman and Ninkov, Marina and Wardell, Christine M and Benoit, Jenna M and Wang, Nicole I and Meilleur, Courtney E and D'Agostino, Michael R and Zhang, Ali and Feng, Emily and Saeedian, Nasrin and Bell, Gillian I and Vahedi, Fatemeh and Hess, David A and Barr, Stephen D and Troyer, Ryan M and Kang, Chil-Yong and Ashkar, Ali A and Miller, Matthew S and Haeryfar, S M Mansour},
title = {Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011485}
}
EUVIMED